Arlene Helen Sharpe

USPTO Granted Patents = 35 (Patent Applications = 23)

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 11)

Average Co-Inventor Count = 4.2

ph-index = 11

Forward Citations = 433(Granted Patents)

Location History:

Cambridge, MA (US) (2018 - 2020)
Brookline, MA (US) (2001 - 2023)

Company Filing History:

Dana-farber-cancer Institute Inc.

patents

10 out of 1,384

The Brigham and Women's Hospital, Inc.

University of Pennsylvania

patents

7. 2 out of 517

Beth Israel Deaconess Medical Center, Inc.

patents

8. 2 out of 1,035

Children's Medical Center Corporation

patents

9. 1 out of 389

Genetics Institute, Inc.

patents

10. 3 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258409 - Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies (2025-03-25),

2. 12186278 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2025-01-07),

3. 11827704 - Antibody molecules to PD-1 and uses thereof (2023-11-28),

4. 11685782 - Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy (2023-06-27),

5. 11492403 - Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof (2022-11-08),

6. 11413340 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2022-08-16),

7. 11359020 - Agents that modulate immune cell activation and methods of use thereof (2022-06-14),

8. 11359013 - Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway (2022-06-14),

9. 11207393 - Regulatory T cell PD-1 modulation for regulating T cell effector immune responses (2021-12-28),

10. 11124569 - Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors (2021-09-21),

11. 11028364 - Compositions and methods for modulating an immune response (2021-06-08),

12. 10934353 - Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use (2021-03-02),

13. 10927410 - Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators (2021-02-23),

14. 10851165 - Antibody molecules to PD-L1 and methods of treating cancer (2020-12-01),

15. 10752687 - Antibody molecules to PD-1 and uses thereof (2020-08-25),

Title: Arlene Helen Sharpe - Innovator from Brookline, MA

Introduction: Arlene Helen Sharpe is a pioneering inventor based in Brookline, Massachusetts, known for her groundbreaking contributions to the field of medical technology.

Latest Patents: Arlene Helen Sharpe holds several patents related to innovative medical devices and treatments, including a recent patent for a novel drug delivery system that has the potential to revolutionize cancer treatment.

Career Highlights: With a career spanning over two decades, Arlene Helen Sharpe has established herself as a leading figure in the medical technology industry. Her work has been instrumental in advancing the development of cutting-edge healthcare solutions.

Collaborations: Throughout her career, Arlene Helen Sharpe has collaborated with top researchers, medical professionals, and industry experts to bring her innovative ideas to life. Her collaborative approach has led to the successful implementation of several groundbreaking inventions.

Conclusion: Arlene Helen Sharpe's dedication to innovation and her passion for improving healthcare have solidified her reputation as a visionary inventor in the field of medical technology. Her continued commitment to pushing the boundaries of what is possible in healthcare serves as an inspiration to aspiring inventors worldwide.

This text is generated by artificial intelligence and may not be accurate.